GLP-1 Receptor Agonists Obesity Drugs Market Regional Analysis North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, driven by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide Patients and providers in the region increasingly value the superior weight loss efficacy, cardiovascular benefits, and convenience of long-acting GLP-1 drugs such as semaglutide (Wegovy) and tirzepatide (Zepbound), which have become key components in chronic weight and metabolic disorder management This widespread use is further supported by favorable reimbursement policies, high healthcare spending, and a proactive medical community, positioning North America as the leading hub for innovation and growth in the GLP-1 obesity drugs space U.S
This triple-agonist approach targets GLP-1, GIP, and glucagon receptors, creating a synergistic effect that produces weight loss results exceeding anything previously achieved in clinical trials
The IgG4 Fc region was selected and its sequence modified at several positions to further reduce its interaction with the Fc-y receptors to avoid ADCC immunologic side effects [86]
France allows pharmacist substitution for biosimilars on a designated list
Diabetes was induced by the single intraperitoneal injection of STZ (45 mg/kg)
